Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Darlifarnib |
| Synonyms | |
| Therapy Description |
Darlifarnib (KO-2806) is a farnesyltransferase inhibitor, which may inhibit the Mtor pathway, leading to cell cycle arrest and inhibition of cell growth (Mol Cancer Ther (2023) 22 (12_Supplement): B024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Darlifarnib | KO 2806|KO2806|KO-2806 | Farnesyltransferase Inhibitor 4 | Darlifarnib (KO-2806) is a farnesyltransferase inhibitor, which may inhibit the Mtor pathway, leading to cell cycle arrest and inhibition of cell growth (Mol Cancer Ther (2023) 22 (12_Supplement): B024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06026410 | Phase I | Cabozantinib + Darlifarnib Adagrasib + Darlifarnib Darlifarnib | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) | Recruiting | USA | ITA | FRA | ESP | 0 |